Serina Therapeutics, Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Serina Therapeutics eliminated its Series A Convertible Preferred Stock (965,250 authorized shares) from its certificate of incorporation on October 2, 2026. All issued shares of Series A Preferred had been converted to common stock; the company returned these shares to undesignated preferred stock status. This is a routine capital structure cleanup with no financial impact.
Why this rating
Administrative elimination of fully-converted preferred stock. No cash, assets, or equity value affected. Routine corporate housekeeping, immaterial to $21.8M company valuation.
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.